What makes UpToDate so powerful?

  • over 11000 topics
  • 22 specialties
  • 5,700 physician authors
  • evidence-based recommendations
See more sample topics
Find Print
0 Find synonyms

Find synonyms Find exact match

Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jul 2017. | This topic last updated: Jul 06, 2017.

INTRODUCTION — Lymphangioleiomyomatosis (LAM) is a rare multisystem disease that mostly afflicts young women [1-4]. While in the past surgical biopsy was a commonplace approach for the diagnosis of LAM, there is now a paradigm shift in practice towards less invasive methods that obviate the need for surgery in most patients.

The clinical features and diagnostic evaluation of LAM will be reviewed here. The epidemiology, pathogenesis, treatment, and prognosis of sporadic and tuberous sclerosis complex (TSC)-associated LAM are discussed separately. (See "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis" and "Sporadic lymphangioleiomyomatosis: Treatment and prognosis" and "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis" and "Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults".)

DEFINITION — The term sporadic LAM is used for patients with LAM not associated with tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that is associated with TSC.

CLINICAL MANIFESTATIONS — LAM commonly afflicts young females (see 'General' below). The presenting symptoms and signs of LAM vary depending upon the organs affected by the disease. Most commonly, patients have the signs and symptoms of lung disease (see 'Pulmonary' below) but can also present with symptomatology arising from disease in extrapulmonary sites, especially renal angiomyolipomas and the lymphatic vasculature [5,6] (see 'Non pulmonary' below). Neurocutaneous findings and disease manifestations that are typical of tuberous sclerosis complex (TSC; eg, angiofibromas, Shagreen patches, cortical tubers, seizures, cognitive impairment, etc) are absent in sporadic LAM.

General — Patients with LAM are mostly premenopausal (approximately two-thirds in most trials and registries) women [7]. While the average age at presentation is typically between the mid-thirties and mid-forties, the range extends from preadolescence to elderly (>80 years) [4,7-15]. Prepubertal LAM is rare [16]. It has been postulated that the increase in mean presentation age over the past decade or so may be due to increased awareness, an increased index of suspicion for LAM, and the increasing detection of cysts by computed tomography (CT) in patients under evaluation for chronic obstructive pulmonary disease (COPD), asthma, or other chronic pulmonary disorders [17]. LAM occurs in men, but is rare, thus far exclusively in men with TSC, and almost always asymptomatic. (See "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Epidemiology'.)

In some patients, symptom onset and diagnosis occur while the patient is receiving estrogen replacement therapy (eg, oral contraception, fertility treatment) or is pregnant. [18-29].

Although in our experience, LAM can affect all races, one study suggested that LAM is more common in white females with a higher socioeconomic status, an observation that likely reflects differential access to information [7].

Pulmonary — The presenting characteristics of patients with LAM were best illustrated in a United States registry that enrolled 230 patients [7]. The most common manifestations in this study are supported by smaller studies performed before and after that publication [1,8,9,18,30-36]:

Fatigue (70 percent)

Progressive dyspnea (70 percent)

Spontaneous pneumothorax (36 percent)

Chest pain (<10 to 15 percent)

Cough or phlegm (<10 to 15 percent)

Pleural effusion (21 percent)

Pulmonary hypertension (<7 percent)

Chest tightness or dyspnea that varies with the menstrual cycle (<10 percent)

Chyloptysis (7 percent)

Chyle in urine, vaginal discharge, stool (<10 percent)

Hemoptysis (<5 percent)

Dyspnea during exercise is the most common presenting symptom in LAM. As dyspnea is nonspecific and LAM is rare, women are often labeled with a diagnosis of asthma, emphysema, or COPD before LAM is suspected. Furthermore, up to one-third of women with LAM also have reversible airflow obstruction, which can add to confusion with other obstructive lung diseases [32,37,38].

Pneumothorax is the presenting complaint in one-third of patients, and occurs during the course of the disease in up to two-thirds of patients [7,18,39,40]. Recurrences are frequent. In one observational study, in those with recurrent pneumothorax, the mean number of pneumothoraces was four (ipsilateral, contralateral, or bilateral) [7]. Patients with larger cysts may be more likely to present with a pneumothorax [41]. It has been suggested that women who present with pneumothorax have a more benign course than those who present with dyspnea [17], although ascertainment earlier in the course of disease likely confounds interpretation of this observation. (See "Secondary spontaneous pneumothorax in adults", section on 'Treatment'.)

Pleural effusions are most commonly due to chylothorax, occurring in 10 to 30 percent of women with LAM [18,42]. One systematic review of 94 studies reported that chylous effusions were typically unilateral (76 percent) and right-sided, although bilateral effusions can also occur [35]. Biochemical parameters may reveal an exudative effusion with the typical features of chyle (eg, high triglyceride, cholesterol, chylomicrons). Chylothorax volume varies and can be quite stable over time. Pleural chyle may arise from sources in the abdomen; pumped into the thorax by the bellows action of the chest, but more often occurs in the absence of chylous accumulation in the peritoneum (<5 percent) or elsewhere. (See "Etiology, clinical presentation, and diagnosis of chylothorax", section on 'Pleural fluid analysis'.)

Lymphatic pulmonary congestion due to reflux of chyle from the axial lymphatics into the pulmonary lymphatic circuit can result in worsening shortness of breath associated with chyloptysis or chylous pleural effusion. Chest radiographs and computed tomographic studies may reveal ground glass or an interstitial pulmonary edema pattern with septal thickening [43-45]. Further details regarding the lymphatic manifestations of LAM are provided separately. (See 'Lymphatic manifestations' below.)

Resting pulmonary hypertension (PH) is uncommon (<7 percent) in LAM, but exercise-induced increases in pulmonary pressures occur [46-48]. In a series of 120 patients with LAM, 7 percent had resting PH on echocardiography, and approximately 50 percent experienced a decline in oxygen saturation with exertion, which correlated with a rise in pulmonary artery pressure (PAP) [46]. In a separate report, intrapulmonary arteriovenous shunts were demonstrated by contrast echocardiography in a small number of patients with LAM who developed hypoxemia and increased pulmonary artery systolic pressure during exercise [47]. Another retrospective study of 20 women with LAM who had PH by right heart catheterization found that when present, PH was typically mild (mean PAP 32 mmHg) [48]. (See "Clinical features and diagnosis of pulmonary hypertension in adults".)

The physical examination in patients with LAM is often unrevealing, but may demonstrate wheezes, hyperinflation, decreased or absent breath sounds, ascites, and intra-abdominal or adnexal masses. Clubbing is rare [36,49,50]. Characteristic features of TSC (eg, subungual fibromas, facial angiomas, hypomelanotic macules) are absent in sporadic LAM. (See "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis", section on 'Clinical features'.)

Non pulmonary

Renal angiomyolipomas — Renal angiomyolipomas (AML) are benign masses that contain blood vessels, muscle tissue, and fat. They occur in approximately 30 percent of patients with sporadic LAM (compared with >80 percent in patients with TSC-LAM) (image 1A-B) [7,51-53]. While renal AMLs may be asymptomatic (especially small lesions), patients with lesions larger than 4 cm, especially those that contain aneurysms, may present with the features of hemorrhage (abdominal pain and a mass). Rarely, AMLs may grow to enormous size prior to clinical detection in patients with sporadic LAM, but do not typically affect renal function in the absence of TSC. If AMLs are large, bilateral, or multiple, then TSC should be suspected (80 to 100 percent of patients with TSC have AMLs). (See "Renal manifestations of tuberous sclerosis complex" and "Renal angiomyolipomas" and 'Abdominal imaging' below.)

Small AMLs may be encountered incidentally in abdominal CT imaging done for another reason. For those in the general population who present with an AML, especially when multiple or bilateral, a low threshold for performing a CT of chest is prudent given that approximately 11 percent of patients with sporadic AMLs have cystic changes in the lung consistent with LAM [54].

Lymphatic manifestations — Lymphatic manifestations are much more common in sporadic LAM than TSC-LAM [55].

Chylothorax and chyloperitoneum — Chylothorax is the most common lymphatic manifestation of LAM (10 to 30 percent) (image 2) [5-7,18,42,56]. These patients may present with a pleural effusion or chyloptysis. (See 'Pulmonary' above.)

Less commonly, chylous accumulation can result in the following:

Chyloperitoneum (also known as chylous ascites), which occurs in approximately 4 percent, may present with abdominal swelling or chyle leak from the umbilicus

Chyluria, which is thought to be due to lymphangioleiomyomatous connections between dilated retroperitoneal lymphatics and the renal collecting system, is seen in 2 percent of reported cases

Lymphatic pulmonary congestion due to reflux of chylous fluids from axial lymphatics into pulmonary lymphatic circuit (<1 percent)

Chylopericardium (<1 percent)

Vaginal chyle (chylometrorrhea (<1 percent)

Chyle in stool (chylocolporrhea) with or without protein losing enteropathy (<1 percent)

Lymphangioleiomyomas — Lymphangioleiomyomas (also known as lymphangiomyomas) of the retroperitoneum and pelvis, and less commonly, the mediastinum, are lymphatic fluid-filled, benign tumors that occur in 16 to 38 percent of patients with LAM [57-60]. They may be asymptomatic or present with nausea, bloating, abdominal pain, edema of the lower extremities, or urinary symptoms (eg, frequency due to bladder displacement or chyluria due to lymphangioleiomyomatous connections with the renal collecting system). Worsening of symptoms as the day progresses may be explained by diurnal variation in size of the tumors due to gravity, dietary intake, or exercise [59]. Lymphedema of the lower extremities and buttocks was described in 8 of 228 patients with sporadic LAM in Japan [61]; all eight patients had enlarged retroperitoneal or pelvic lymph nodes, thought to be lymphangioleiomyomas. (See 'Abdominal imaging' below.)

Lymphadenopathy — Enlarged axial lymph nodes are not uncommon, with reports ranging from 25 to 77 percent of patients with pulmonary LAM [5,18,36,51,62]. Retroperitoneal and pelvic lymphadenopathy is more common than mediastinal and hilar node involvement, consistent with an origin in the pelvis or low abdomen [63]. There are sparse case reports of LAM in supraclavicular and groin nodes [64-66]. LAM has been reported in lymph nodes biopsied during evaluation for suspected lymphoma or pelvic mass, or during staging of a known uterine or ovarian cancer [67,68].

Although the yield is uncertain, in our practice, incidental discovery of LAM in an axial lymph node prompts an evaluation for cystic lung disease with a chest CT.

Uterine LAM lesions — Several reports of LAM lesions in the uterus, ovaries, and adnexa have been published [69-71]. As an example, LAM lesions were discovered in uterine specimens from 9 of 10 patients with pulmonary LAM [72]. The lesions were more profuse and diffusely distributed in the myometrium of uterine specimens from patients with TSC-LAM, and more sparse and subadventitial in the specimens from sporadic LAM patients.

Uterine leiomyomas (fibroids) are common in LAM but do not appear to be more common in women with LAM than in the general population.

Other — An increased incidence of cerebral meningiomas has been reported in LAM [73], although meningiomas are common in the general population, and the validity of the association has been challenged [74].

Angiomyolipomas of the liver and spleen, and sclerotic bone lesions also occur in patients with sporadic LAM but are more common in TSC-LAM [6,55,72,73,75,76]. (See "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Lam cell origin'.)

EVALUATION — LAM should be suspected in women with a spontaneous pneumothorax or unexplained dyspnea, especially non-smoking women of reproductive age. LAM should also be suspected in women (and less commonly in men) with tuberous sclerosis complex (TSC) as well as in those who present with pleural or peritoneal chylous accumulations or a renal angiomyolipoma. The following sections outline the evaluation of suspected LAM, which includes pulmonary function testing, chest imaging, and selected laboratory testing (algorithm 1). For patients who have previously undergone such testing, careful review of the existing data looking for clues to the presence of LAM is prudent. As an example, with the growing use of computed tomography (CT) of the chest and abdomen, thin-walled cysts characteristic of the diagnosis are increasingly discovered incidentally.

In general, these recommendations are consistent with guidelines set out by international societies and modified as new data arise [57,77,78].

Pulmonary function tests — Pulmonary function tests (PFTs), including spirometry with and without bronchodilator testing, lung volumes, and diffusing capacity for carbon monoxide (DLCO), are an essential component of the evaluation of dyspnea and should be performed in women suspected to have LAM. However, PFTs are diagnostically nonspecific and a normal study does not preclude the diagnosis. When indicated by symptoms, severity of lung function impairment (eg, low DLCO or forced expiratory volume in one second [FEV1]) or reduced resting pulse oxygen saturation <95 percent, a six-minute walk test and/or arterial blood gas analysis can be used to assess the need for supplemental oxygen at rest or with exertion [79]. Nocturnal oximetry can be obtained to assess the need for oxygen with sleep. (See "Overview of pulmonary function testing in adults" and "Office spirometry" and 'Imaging' below.)

The proportions of women who present with mild, moderate, or severe lung disease varies widely based on mode of ascertainment in different populations, and with increased use of CT scanning "incidental" detection of lung cysts is expanding the proportion of women who are discovered to have asymptomatic disease [33]. However, observational studies consistently report the following findings on PFTs in women with LAM [7,9,31,33,34,36,49]:

Normal spirometry (30 to 60 percent)

Obstructive pattern on spirometry (25 to 66 percent)

Restrictive or mixed obstructive and restrictive pattern on spirometry (less than one quarter)

Reduced DLCO (60 to 90 percent)

Approximately 30 percent of patients demonstrate reversible airflow obstruction following an inhaled bronchodilator [18,37]. In a study of 130 patients with baseline airflow limitation who underwent testing on multiple occasions, 39 patients demonstrated reversibility in airflow obstruction after administration of an inhaled bronchodilator, including 9 to albuterol, 12 to ipratropium, and 18 to both [37]. The patients with a positive bronchodilator response had a lower baseline FEV1. The mechanism of airflow obstruction is unclear, but possible explanations include loss of elastic recoil or LAM cell involvement of bronchial airways [32,80-82].

Lung volumes may be elevated in LAM (due to hyperinflation), resulting in an increased total lung capacity (TLC), residual volume (RV), and RV/TLC ratio. However, lung volumes may also be normal or reduced.

Diffusing capacity is reduced in the majority of patients with LAM, even in those with normal spirometry [7,31,49]. Thus, an isolated reduction in DLCO in a young woman with dyspnea should prompt consideration of a chest CT to look for cysts characteristic of LAM, once other common causes of reduced DLCO such as anemia have been excluded. Several reports indicate that DLCO correlates with disease severity as assessed by CT, histology, and exercise testing [83-86].

Resting, nocturnal, or exercise-induced hypoxemia and (rarely) hypercapnia may be present in those with more advanced disease, and a six-minute walk test with oximetry and/or arterial blood gas analysis may be warranted determine if supplemental oxygen is needed [51,79,87]. (See "Overview of pulmonary function testing in adults", section on 'Six-minute walk test'.)

Although useful as a research tool, cardiopulmonary exercise testing (CPET) is generally not indicated for the routine diagnosis and management of women with suspected LAM. However, it is often performed as part of the evaluation of unexplained dyspnea. Characteristic findings are those of decreased pulmonary reserve with or without pulmonary vascular dysfunction, although obstruction only partially explains reduced physical activity in this population [32,81,88,89]. Other findings that might be observed during CPET in patients with LAM include reduced oxygen consumption, low anaerobic threshold, abnormal and excessive ventilatory response, with a high respiratory rate, excessive minute ventilation, and reduced breathing reserve, abnormal baseline or exercise dead space to tidal volume (VD/VT) ratio, and dynamic hyperinflation. (See "Functional exercise testing: Ventilatory gas analysis".)

PFTs are important in assessing baseline disease severity as well as following lung function over time since [90]. There is a very low risk of pneumothorax during lung function or exercise testing in this setting [91]. (See 'Assessment of disease extent' below.)

Imaging — Noncontrast high-resolution computed tomography (HRCT) of the chest should be performed in women with suspected LAM to look for pulmonary cysts characteristic of the disease. In most cases, the decision to pursue HRCT is triggered by recurrent pneumothorax, chylothorax, or relentlessly progressive dyspnea on exertion, although an increasing proportion of women are presenting with evidence of characteristic thin walled, diffusely distributed pulmonary cysts on chest or abdominal CT performed for a different indication. Noncontrast abdominopelvic CT is indicated to look for the presence of angiomyolipomas if cysts are found on chest CT or the patient has abdominal or pelvic symptoms or signs that warrant dedicated abdominal imaging (eg, sudden flank pain). The spectrum of radiographic findings in women with LAM are discussed in the sections below.

Chest radiograph — A chest radiograph is typically obtained in patients with unexplained dyspnea, particularly when dyspnea is acute in onset. In patients with LAM, the chest radiographic findings are variable (image 3A-B) [1,7,49,92,93]. These include a normal radiograph (early in the course of the disease), reticular or nodular opacities (from the compression of lung tissue by dilated cystic airspaces), hyperinflation (33 to 62 percent of patients), emphysematous-like changes, pleural effusion (often due to a chylothorax), pneumothorax, or lymphadenopathy. The findings on plain chest radiograph are often uninformative or nonspecific, and are never sufficient to diagnose LAM.

Chest computed tomography — The rationale for performing noncontrast HRCT of the chest in patients suspected of having LAM is based upon the principles that thin-walled cysts, the hallmark lesion in LAM, are seen in almost every patient with LAM and that cysts are often undetectable on routine chest radiography (image 4A-C) [51,94-96].

The following features may be found on HRCT chest:

Cysts – Pulmonary cysts are the hallmark feature of LAM on HRCT chest. Cysts characteristic of LAM are thin walled, diffuse, round, well-defined, bilateral, and without lobar predominance (image 5) [55,57,62,63,92,95,97,98]. They vary in size ranging from 2 to 40 mm in diameter and typically have walls ranging from 0.1 to 2 mm in thickness. The cysts are typically devoid of internal structures (eg, centrilobular vessels or septae) or consistent relationships with adjacent vessels, airways, or interlobular septae.

Although cystic change in the lung parenchyma progresses over time, no natural history studies have clearly delineated when cysts begin to develop or their rate of progression. Similarly, because isolated cysts are occasionally found in healthy nonsmoking subjects, it is important to set a threshold for the number of cysts in any one individual that is considered to be abnormal. While some experts have suggested a cut-off of >3 [54], we and other experts usually select a higher cut-off >10 cysts, such that LAM should be highly suspected in women with more than 10 typical cysts [57]. The likelihood of LAM may be lower in those with fewer cysts (eg, >2 and ≤10), but LAM is still theoretically possible in such cases. While the 10 cyst cut-off is arbitrary and needs to be validated in formal studies, it was chosen in part to discourage lung biopsy in asymptomatic patients with very few cysts and normal lung physiology. The approach to biopsy in those with atypical cysts is discussed below. (See 'Atypical presentations' below.)

Pneumothorax – Pneumothorax is the presenting manifestation in approximately 36 percent of patients with sporadic LAM (image 6) (see 'Pulmonary' above). Asymptomatic pneumothorax may be identified in approximately 5 percent of patients undergoing chest CT in the absence of acute symptoms [63]. Chronic loculated pneumothoraces may be noted (image 3A-B) [7]. (See "Secondary spontaneous pneumothorax in adults".)

Pleural masses or thickening – Macroscopic pleural masses and thickening are not a natural feature of LAM, although microscopic pleural involvement is common. Among patients who have undergone pleurodesis for recurrent pneumothorax prior to diagnosis, pleural thickening and complex pleural masses may be apparent [99-101]. The masses in patients who have received talc for pleurodesis may be solid and hyperdense, contain areas of calcification, and are often positron emission tomography (PET)-positive for many years after pleurodesis suggesting ongoing inflammation [102].

Thoracic lymphatic involvement and pleural effusion – Lymphatic involvement by LAM can cause septal thickening, unilateral or bilateral chylothorax (10 to 20 percent), mediastinal lymphadenopathy (26 percent; hilar adenopathy is unusual), dilated thoracic duct (11 percent), pericardial effusion (6 percent), or rarely cystic lymph nodal lesions typical of lymphangioleiomyomas [18,43,46,62].

Other – Additional features on HRCT include:

Ground glass opacities (GGOs) and septal thickening – GGOs are rare but may represent compression from airtrapping and hyperinflation in adjacent cystic lung parenchyma, pneumonia, pulmonary edema, or alveolar filling with blood or lymphatic fluid [103]. Septal thickening may be present due to lymphatic obstruction [62].

Multifocal micronodular pneumocyte hyperplasia – Features of multifocal micronodular pneumocyte hyperplasia (MMPH) may be encountered in LAM patients with TSC. Although rarely reported in subjects for sporadic LAM, we suspect these cases may represent clinically occult TSC [104]. (See "Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults", section on 'Clinical manifestations'.)

Renal angiomyolipomas (AMLs) – Renal AMLs may be incidentally found in women with LAM on HRCT. (See 'Abdominal imaging' below.)

Abdominal imaging — In patients with suspected LAM who have characteristic cysts on chest CT, the abdominal sections of the chest CT should be reviewed for renal AMLs. Whether present or not, most experts obtain additional abdominal-pelvic imaging to determine the presence and extent of AML involvement [57], most commonly a CT scan or magnetic resonance imaging (MRI). Ultrasound (USG) may be a reasonable alternative but is less sensitive and less accurate, especially for small lesions. The rationale for this approach is that the prevalence of renal AMLs is high in sporadic LAM [6] and, when present, AMLs can provide the basis for a clinical nonpathologic diagnosis of LAM, thereby obviating the need for biopsy. Less commonly, evidence of lymphatic involvement may be found on CT, which may support a diagnosis of LAM (eg, lymphangioleiomyomas) or provide the clinician with a less invasive alternative to lung biopsy (eg, cytological evaluation of a lymph node aspirate or chylous fluid).

Renal AMLs – Renal AMLs occur in approximately one-third of women with sporadic LAM, which is much less frequent than in those with TSC-LAM (>80 percent) [7,53,105,106]. Most renal AMLS can be readily identified and diagnosed radiographically, typically by the presence of fat within a renal tumor on noncontrast-enhanced CT (image 7 and image 8). Fat-free or fat-poor AMLs can also occur, and must be distinguished renal cell carcinomas, oncocytomas, or other more aggressive neoplasms, which can rarely complicate TSC and sporadic LAM. MRI can be helpful in some of these cases because it is more sensitive than CT for detecting fat density [51]. Imaging findings must be carefully interpreted because hemorrhage into an AML can produce a complex renal mass that may be confused with a renal cell carcinoma (RCC) and small amounts of fat can be rarely found in RCCs. Knowledge of a pre-existing AML and the presence of fat attenuation may help in the differentiation of these entities [99]. Ultrasound is typically less sensitive than CT for detection of small lesions and MRI is useful for assessing tissue composition (fat, vessel, etc) and aneurysmal content, which is helpful in assessing the risk of hemorrhage. When the diagnosis remains in question, needle aspiration may be an alternative to surgical biopsy for diagnosis. Further details regarding the diagnosis of AMLs are provided separately. (See "Renal angiomyolipomas", section on 'Diagnosis' and "Renal manifestations of tuberous sclerosis complex", section on 'Angiomyolipomas'.)

Lymphadenopathy – Axial lymphadenopathy is common and peripheral lymphadenopathy is very rare in LAM. Retroperitoneal lymphadenopathy is reported in up to 77 percent of patients [36,51]. Lymph node involvement is rare in the supraclavicular and inguinal regions and common in the pelvis and abdomen. Low density within enlarged axial lymph nodes can lead to confusion with lymphoma or necrotizing neoplasms. (See 'Lymphatic manifestations' above.)

Lymphangioleiomyomas – Lymphangioleiomyomas are benign neoplasms of lymphatic vessels (perivascular epithelioid cell tumors [PEComas]) that are found in up to 20 percent of patients with LAM [59]. Proliferation of smooth muscle cells in the lymph vessels results in mural thickening, obstruction, dilation, and pooling of chyle. Radiologically, they have distinct outer walls and appear as dilated fluid-filled spaces. They are found more commonly in the retroperitoneum or pelvis compared with the mediastinum. Lymphangioleiomyomas can exhibit substantial diurnal variation in size, sometimes increasing with eating and exercise and decreasing with fasting [59,60,99]. These features can be useful information for differentiating lymphangioleiomyomas from other neoplasms such as lymphoma.

Other – Other features that can be found on abdominal CT include liver and spleen angiomyolipomas as well as abdominal fluid that may represent chylous ascites [63].

Other imaging

Ventilation perfusion scan – Ventilation-perfusion scans are frequently abnormal in LAM, revealing a distinctive speckled pattern on the ventilation images, but they are not routinely performed for diagnostic purposes [51].

Positron emission tomography (PET) – 18-fluorodeoxyglucose (FDG)-PET is not typically performed since LAM is a slow-growing, low-grade neoplasm that does not take up FDG efficiently. However, should PET be positive, an alternate diagnosis (eg, lymphoma, cancer, PEComa) or reason (inflammatory lesion) should be sought [102].

Advanced lymphatic imaging – Lymphatic imaging is not typically performed for diagnostic purposes but can be helpful to guide therapeutic decisions in patients with problematic pleural effusions [107]. (See "Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Chylothorax and chylous ascites'.)

Laboratory — There are no specific laboratory features that, taken in isolation, are diagnostic of LAM. A few tests are helpful in excluding other causes of cystic lung disease, such as alpha-1 antitrypsin levels and Sjögren antibodies. In patients who have suspected LAM with cystic lung disease on chest CT, vascular endothelial growth factor-D (VEGF-D) is performed by many experts. In this population, VEGF-D narrows the differential diagnosis and directs patient selection for lung biopsy.

Vascular endothelial growth factor-D — We suggest that VEGF-D levels be measured in the serum of patients with suspected LAM, in whom typical thin-walled cysts are found on chest CT. The rationale for this approach is that several studies have shown that serum levels of VEGF-D are elevated in up to two-thirds of women with LAM [108-116] and that a level ≥800 pg/mL reliably distinguishes LAM from other cystic lung diseases [109,112,113,116]. The major drawback for testing is that VEGF-D analysis is currently available in the US as a College of American Pathologists/Clinical Laboratory Improvement Act (CAP/CLIA)-certified test only through the Translational Trials Laboratory at Cincinnati Children's Hospital Medical Center. The LAM Foundation website lists the centers in Europe and Asia that offer the test and describes the proper collection, handling, and shipping of VEGF-D specimens.

The ability of VEGF-D to distinguish LAM from other etiologies of cystic lung disease was best illustrated in a study of 195 women with cystic lung diseases due to several etiologies including LAM [109]. Serum VEGF-D levels were significantly greater in sporadic LAM (median 1175 pg/mL versus 281 pg/mL) than in other cystic lung diseases. When a cut-off of VEGF-D ≥800 pg/mL was used, the sensitivity and specificity of serum VEGF-D to diagnose LAM were 71 and 100 percent, respectively. Similar results were obtained in other VEGF-D studies, although differences between laboratories in the normative ranges [111] and the use of normal volunteers instead of cystic lung disease controls limits direct comparisons [113-115]. Importantly, a negative VEGF-D level (<800 pg/mL) should not be used to exclude the diagnosis of LAM and the test has only been validated in women with cystic change that is compatible with LAM [109]. VEGF-D would not likely be useful for population screening in the absence of documented cystic change on CT, since even a near perfect specificity of 99.9 percent would lead to too many false positives.

The optimal approach in those with a VEGF-D between 600 and <799 pg/mL is less certain. Although a cut-off ≥600 pg/mL has a diagnostic sensitivity and specificity of 84 and 98 percent, respectively, false positives are highly undesirable, especially when considering initiating long-term or lifetime exposure to therapies such as mechanistic target of rapamycin inhibitors that have significant side effects. Thus, we and other experts use a cut-off of ≥800 pg/mL and consider VEGF-D ≥600 pg/mL to be meaningful only in lower risk situations, such as for patients who are not interested in therapies or interventions. (See 'Atypical presentations' below.)

This approach is supported by the American Thoracic Society guidelines on the evaluation and management of LAM [77]. The European Respiratory Society [57] did not provide guidance on VEGF-D testing since they were written several years before data supporting the role of VEGF-D were published.

The value of VEGF-D testing as a biomarker for disease progression and response to treatment, and as a screening tool for young women with TSC is discussed separately. (See "Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults" and "Sporadic lymphangioleiomyomatosis: Treatment and prognosis" and "Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Abnormal lymphangiogenesis' and "Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Monitored observation'.)

Other — Other laboratory tests that are commonly ordered as part of the investigation for cystic lung disease include testing for alpha-1 antitrypsin (AAT) deficiency and autoantibody testing for rheumatic diseases that can mimic LAM, such as rheumatoid factor (RF), anti-nuclear antibody (ANA), and Sjögren related antibodies (SSA/Ro and SSB/La antibodies). (See "Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency", section on 'Evaluation and diagnosis' and "Diagnosis and classification of Sjögren's syndrome".)


General principles — Surgical lung biopsy was the original gold standard for definitive diagnosis of LAM. However, surgical lung biopsy is not always necessary and a confident diagnosis can often be achieved less invasively (algorithm 1). Thus, there has been a paradigm shift in practice that involves the following:

Obtaining a clinically confident diagnosis through the least invasive means possible using an approach that integrates clinical, radiological, and laboratory data. Observational data suggest that utilizing such strategies reduces the need for biopsy by as much as 60 to 80 percent [113]. (See 'Clinical nonpathologic diagnosis' below.)

Limiting the patients who are referred for lung biopsy for diagnosis to those in whom a confident diagnosis cannot be achieved using less invasive methods. (See 'Definitive pathologic diagnosis' below.)

Referral to a specialized center, particularly when deciding whether to pursue a lung biopsy, is recommended for centers and clinicians with limited experience with LAM. (See 'Additional resources' below.)

We base our approach to the diagnosis of LAM on the following factors:

Mode of presentation – The approach to a pathological diagnosis of LAM varies based on presentation.

Typical presentations – Most experts agree on what constitutes typical presentations that meet criteria for a clinically confident diagnosis (eg, typical cysts plus tuberous sclerosis complex [TSC]). For patients with typical cysts who do not meet criteria for a clinically confident diagnosis, the presence of tissue or fluid that is more readily accessible (eg, effusion that can be tapped or lymph node accessible by endobronchial ultrasonography) presents diagnostic opportunities that are less invasive than lung biopsy. Similarly, a lung biopsy performed at the time of therapeutic pleurodesis for recurrent pneumothorax carries limited additional risk compared with a separate biopsy procedure. (See 'Characteristic cysts with supportive features' below and 'Characteristic cysts alone on computed tomography' below.)

Atypical presentations – For those with atypical presentations, there are no clear guidelines and the approach should be individualized. (See 'Atypical presentations' below.)

Therapeutic impact of definitive diagnosis – The decision to pursue lung biopsy in patients with cystic lung disease of unknown etiology should take into consideration the availability of therapies or interventions that can affect the outcome of the diseases in the differential (eg, mechanistic target of rapamycin inhibitors, alpha-1 antitrypsin replacement therapy, or cessation of smoking). (See "Sporadic lymphangioleiomyomatosis: Treatment and prognosis".)

Assessment of risk and benefit – Decisions regarding the importance of obtaining a pathological diagnosis are based upon assessments of risks and benefits. As examples, observation may be appropriate in patients with only a few cysts and normal lung function, as well as in post-menopausal patients with mild disease (ie, when disease progression is known to be slower). In addition, the value of establishing a definitive diagnosis by biopsy in patients with severe end-stage lung disease approaching lung transplantation is questionable. (See 'Choosing transbronchial or surgical lung biopsy' below.)

The values and preferences of the patient – Some patients place a high value on diagnostic certainty and are willing to accept the risk associated with an invasive procedure while others prefer to avoid them. Thus, a risk-benefit discussion is critical so that the decision to pursue biopsy can be a shared one between the patient and the clinician. (See "A patient-centered view of the clinician-patient relationship" and "Discussing goals of care" and "Informed procedural consent".)

We propose the algorithmic diagnostic strategy outlined in the sections below acknowledging that it should be tailored for each individual. This strategy is consistent with that outlined by the American Thoracic Society, but differs slightly from that of the European Respiratory Society, which was published at a time when data on the value of vascular endothelial growth factor-D were not available [57,77].

Characteristic cysts with supportive features — During the diagnostic evaluation of patients with suspected LAM, a surgical biopsy may be avoided in select populations who have characteristic cysts on computed tomography (CT) of the chest (see 'Chest computed tomography' above) and one or more of the features listed in the sections below. A nonpathologic diagnosis may be reached with high certainty (ie, clinically confident diagnosis) in most of these populations. However, in a small proportion, a more definitive diagnosis may be needed and can be obtained cytologically using needle aspiration (ie, less invasive) techniques or pathologically on tissue biopsy of lung or lymph nodes. Reasons that may mandate a more aggressive invasive approach include those who have atypical presentations (especially when considering interventions entailing risk such as mTOR inhibitor therapy), suspicion for an alternate diagnosis, and patient preferences for certainty.

Tuberous sclerosis complex — Patients with TSC and cysts characteristic of LAM on CT do not need to undergo diagnostic lung biopsy due to the high prevalence of LAM and the low likelihood that cysts in TSC are due to a non-LAM-related condition. Patients with sporadic LAM do not have stigmata of TSC (other than angiomyolipomas). However, the features of TSC can be subtle leading to a missed diagnosis. Thus, a thorough history and examination should be performed in patients with suspected sporadic LAM to look for manifestations of TSC (eg, subungual fibromas, facial angiofibromas, hypomelanotic macules, confetti lesions, Shagreen patches, seizures, autism, cognitive impairment). (See "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis", section on 'Clinical features'.)

Genetic testing for mutations in the TSC genes, TSC1 and TSC2, is generally not justified for ruling out tuberous sclerosis in patients who present with apparent sporadic LAM. Screening for TSC manifestations in the brain in this population is controversial and probably has a low yield. When TSC is suspected, patients should be referred to a specialist center for a formal diagnosis. Details regarding criteria for the clinical and genetic diagnosis of TSC are provided separately. (See "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis" and 'Excluding tuberous sclerosis complex' below.)

Renal angiomyolipoma — Patients with characteristic cysts on CT and one or more renal angiomyolipomas (AMLs) do not typically undergo diagnostic lung biopsy. Most experts make a clinical diagnosis of LAM using these criteria that is sufficient to provide an indication for long-term use of mTOR inhibitors. The rationale for avoiding biopsy in this group is based upon the high prevalence of AMLs in women with sporadic LAM, the rarity of AMLs in other cystic lung diseases that mimic LAM, and the risks of biopsy.

However, the clinician should be aware that sporadic AMLs may rarely occur in patients who have cystic lung disease due to other etiologies (eg, Birt-Hogg-Dubé syndrome) [117-119]. In case of diagnostic uncertainty, elevated levels of serum VEGF-D (≥800 pg/mL) can help diagnose LAM, but a normal level is uninformative. Alternative diagnostic strategies may also be considered, such as skin biopsy or genetic testing for Birt-Hogg-Dubé syndrome, or lung biopsy for other etiologies. (See "Birt-Hogg-Dubé syndrome" and "Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2".)

Vascular endothelial growth factor-D positive — We, and other experts, agree that most women with cystic change on CT chest that is characteristic for LAM who also have an elevated VEGF-D level ≥800 pg/mL do not need to undergo lung biopsy. Thus, a clinically confident diagnosis of LAM can be made in this population, which is sufficient to justify proceeding with mTOR inhibitor therapy, when indicated. The rationale for this approach is based upon observational studies that demonstrated the ability of elevated serum VEGF-D to distinguish LAM from other cystic lung diseases [109,116], the details of which are discussed above. (See 'Vascular endothelial growth factor-D' above.)

Although false positive results associated with an elevated VEGF-D level ≥800 pg/mL are rare [120], the decision to pursue lung biopsy for diagnostic purposes in this population should only be made after consultation with a specialized LAM center.

Chylous accumulation — Patients may present with a known chylous accumulation (pleural, peritoneal, pericardial) or alternatively, have a fluid collection(s) suspicious for chyle.

Patients with characteristic cystic change on CT and known chylothorax or chyloperitoneum have a high likelihood of having LAM and, therefore, typically do not undergo biopsy; however, the strength of this association is considered by some experts weaker when compared with the combination of typical cysts with either TSC or AML. Since serum VEGF-D may be reflective of lymphatic involvement in LAM [111] and LAM cell clusters (LCCs) may be found on cytology, we also generally measure VEGF-D levels and/or resample chylous fluid for cytologic analysis, especially when considering mTOR therapy. (See 'Vascular endothelial growth factor-D' above and 'Cytology' below.)

In patients with characteristic cysts and suspected chyle, a sample should be obtained to look for the characteristic biochemical findings of chyle (ie, elevated triglycerides and cholesterol, chylomicrons) and cytologic LCCs, provided sample acquisition is safe and feasible (eg, tiny accumulations, particularly in the pericardial space, may not be suitable).  

Although the diagnostic yield of cytologic analysis of chylous fluids tends to be low in our experience, when LAM cells are identified pathologically, the diagnosis is certain. Thus thoracentesis and cytology can be useful in distinguishing the etiology of chylous effusion in the rare cases where cystic lung diseases that mimic LAM and chylothorax can coexist (eg, lymphoma). Elevated levels of serum VEGF-D can also support the diagnosis. (See "Etiology, clinical presentation, and diagnosis of chylothorax", section on 'Evaluation and diagnosis'.)

The rationale for avoiding biopsy in this population is similar to that in patients with combination of cysts and either TSC or AMLs, that the likelihood of a LAM is high enough such that the risk of lung biopsy is not warranted.

Lymphangioleiomyoma or lymph node disease — Patients may present with a known or suspected lymphangioleiomyoma or lymph nodal LAM:

Patients with characteristic pulmonary cysts on CT and pathologically or cytologically-identified lymphangioleiomyoma or lymph nodal LAM do not need to undergo lung biopsy. Most experts consider these features to be definitively diagnostic and sufficient for eligibility for mTOR inhibitors. In our opinion, in the appropriate clinical setting, the diagnosis of a lymphangioleiomyoma can be made based on radiographic appearance alone.

The optimal approach in patients with cystic change on chest CT who do not already have a pathologic diagnosis of lymph nodal LAM or have an atypical CT appearance of lymphangioleiomyoma is unknown. Elevated levels of serum VEGF-D (≥800 pg/mL) can obviate the need for lung or lymph node biopsy in this population [77]. The choice between lung or lymph node biopsy in those with a negative VEGF-D level should be individualized and depends upon number, location, and size of lymph nodes, the level of confidence of the radiologist that abdominal masses represent lymphangioleiomyomas, severity of underlying lung disease, and patient preferences. When lymph node biopsy is chosen we typically attempt to perform needle aspiration and avoid excisional biopsy since in our anecdotal experience, and that of others, the postoperative course of resective surgery can be complicated by significant and prolonged chyle leak.

Characteristic cysts alone on computed tomography — We suggest that patients with characteristic cysts on chest CT and absence of any other confirmatory features, including pathological or cytological confirmation, TSC, AML, lymphatic manifestations (lymphadenopathy, lymphangioleiomyoma, chylous accumulation) or elevated serum VEGF-D level (>800 pg/mL), sometimes referred to as "lone LAM," should undergo lung biopsy, when a definitive diagnosis is desired by the patient and/or necessary for optimal management. This approach is based upon data that suggest that the classic appearance of cysts on chest CT is not sufficiently diagnostic to support interventions that entail risk, such as long-term exposure to mTOR inhibitors [121-123]. While an expert thoracic radiologist can diagnose LAM based upon chest CT findings alone with a sensitivity of 87 percent and a specificity of 97 percent, the performance of pulmonary physicians was inferior to the radiologists [123], and not every facility has access to an expert thoracic radiologist familiar with the imaging characteristics of LAM and other rare cystic lung diseases. Based on this rationale, and the potential for adverse effects associated with long-term exposure to mTOR inhibitors, we perform lung biopsy in this population. Choosing between transbronchial and surgical lung biopsy is discussed below. (See 'Choosing transbronchial or surgical lung biopsy' below.)

Atypical presentations — The optimal approach to diagnosis in patients who have atypical features of LAM, such as those with non-characteristic cyst distribution, size, or morphology, asymptomatic patients with few cysts and normal lung function discovered on CTs done for another purpose, patients with concurrent interstitial abnormalities, patients with borderline VEGF-D levels (eg, 600 to 799 pg/mL), and men with cystic lung disease, remains unclear. We suggest an individualized approach using the principles outlined above, close monitoring of the disease with frequent clinical and lung function follow-up, and a low threshold to obtain tissue for cytological or pathological examination when candidacy for therapy is dependent on a definitive diagnosis and disease is progressive over time. As an example, patients with a borderline VEGF-D (eg, 600 to 799 pg/mL) and very low cyst burden (perhaps a few dozen cysts), we typically follow conservatively, by monitoring lung function annually and repeating the HRCT at one year. If stability or slow progression is documented, we extend the interval for the next HCRT to three to five years, whereas if progression is more rapid, tissue confirmation may be warranted.

Similarly, atypical presentations of other diseases that mimic LAM should be considered in the differential and an individualized approach used for diagnosis (eg, cyst and AML in Birt Hogg Dubé syndrome, cysts and chylous effusion in lymphoma). Details are discussed below. (See 'Differential diagnosis' below.)

Choosing transbronchial or surgical lung biopsy — The optimal approach for obtaining lung tissue is unknown. Options include transbronchial biopsy, which has a yield of about 60 percent, and surgical lung biopsy, which has a yield approaching 100 percent. Choosing among these options is influenced by several additional factors including clinician experience, disease severity, morbidity of the procedures, and values of the patient. As an example, transbronchial biopsy may be preferred in those who wish to avoid surgery and who accept the lower diagnostic yield and uncertainty regarding pneumothorax risk. In contrast, surgical biopsy may be preferred in those who desire a definitive and expeditious approach, those with a history of an uninformative transbronchial biopsy, or those who are undergoing a therapeutic thoracoscopic pleurodesis for pneumothorax. (See "Secondary spontaneous pneumothorax in adults", section on 'Preventing recurrence'.)

Transbronchial lung biopsy – Several small observational studies report successful diagnosis using transbronchial lung biopsy (TBBx), with yields ranging from 33 to 87 percent of patients with LAM, when an experienced pathologist examines the tissue with appropriate immunohistochemical staining (eg, human melanoma black [HMB]-45, smooth muscle actin) [31,124-131]. The risk of iatrogenic pneumothorax is a concern in the presence of diffuse cystic changes. Although rates of this complication are not reported to be higher than that in other patient populations (about 1 to 5 percent), the true rate in patients with cystic lung disease who undergo transbronchial biopsy is unknown since it has not been prospectively studied. The value of transbronchial cryobiopsy in patients with cystic lung diseases such as LAM remains investigational. (See "Flexible bronchoscopy in adults: Preparation, procedural technique, and complications" and "Flexible bronchoscopy in adults: Associated diagnostic and therapeutic procedures", section on 'Transbronchial biopsy' and "Bronchoscopic cryotechniques in adults", section on 'Cryobiopsy'.)

Surgical lung biopsy – Surgical lung biopsy via video-assisted thoracoscopy, or the more invasive and uncommonly employed thoracotomy approach, has a high diagnostic yield that approaches 100 percent and is the gold standard for the diagnosis of pulmonary LAM. However, surgical biopsy is associated with a higher morbidity, including adverse effects from anesthesia, prolonged air leak, persistent thoracic pain, and, rarely, death. (See "Overview of minimally invasive thoracic surgery".)

Bronchoalveolar lavage is generally not helpful for confirming a diagnosis of LAM, although it can yield useful information when sarcoidosis or pulmonary Langerhans cell histiocytosis is in the differential [130].

DIAGNOSIS — The definitive diagnosis of LAM is made by the identification of LAM cells pathologically or cytologically in lung, lymph node, or body fluid (algorithm 1) [57,77]. While the definitive diagnosis of pulmonary LAM is also dependent upon the identification of typical cystic change in the lung, the diagnosis of extrapulmonary LAM restricted to abdominal or pelvic organs (ie, with no evidence of pulmonary cysts) requires pathological or cytological analysis (see 'Definitive pathologic diagnosis' below). A clinical diagnosis of LAM can also be made using a combination of clinical, radiologic, and laboratory data, the details of which are discussed below. (See 'Clinical nonpathologic diagnosis' below.)

The diagnosis is usually delayed because of the nonspecific nature of the presenting symptoms and rarity of the disease; in one study, patients had symptoms for approximately two years prior to diagnosis [7]. This may improve with the advent of better patient education, improved access to experts knowledgeable in LAM, and the widespread use of chest computed tomography (CT).

Clinical nonpathologic diagnosis — The diagnosis of LAM can be established by high resolution computed tomography (HRCT) of the chest when characteristic cysts are noted in patients who have tuberous sclerosis complex (TSC), renal angiomyolipomas, elevated levels of vascular endothelial growth factor-D (VEGF-D) (≥800 pg/mL), chylous accumulations, and/or typical appearance on CT of lymphangioleiomyomas. (See 'Characteristic cysts with supportive features' above and 'Vascular endothelial growth factor-D positive' above.)

For those with a clinical diagnosis of LAM, an opportunity may arise to make a definitive diagnosis from lung tissue obtained during thorascopic pleurodesis or from chyle that may develop the course of disease progression.

Definitive pathologic diagnosis — A definitive diagnosis of LAM is made by the identification of LAM cells in lung (together with cysts), lymph node, or body fluid. Pathologic and cytologic findings are described in the sections below.

Tissue pathology — The two hallmark histopathologic features of pulmonary LAM are lung cysts and smooth muscle-like LAM cells (picture 1). Histopathologic findings similar to those described in the lung are found in biopsy tissue from lymph nodes but without the cystic change:

Cysts – In pulmonary LAM, the normal architecture of the lung is distorted by multiple small cysts, ranging from 0.1 cm to several centimeters in diameter (picture 2A-C) [1,49].

LAM cells – The primary histopathological abnormality is the proliferation of atypical smooth muscle-like cells (LAM cells) (picture 3A-B and picture 4). The proliferating cells are composed of two types, those that resemble vascular smooth muscle cells, spindle shaped but somewhat shortened and pleomorphic, and more cuboidal cells that have other features of perivascular epithelioid cells (PECs) [132], including clear to granular, lightly eosinophilic cytoplasm located in an immediate perivascular location. The interstitium is thickened, with evidence of LAM cells (or "LAM nodules") around and within the pulmonary lymphatics, venules, and airways [1,30,82]. The lymphatic and venous vessels are often tortuous and dilated. Hemosiderosis is common and is a consequence of clinically insignificant hemorrhage due to the rupture of dilated and tortuous venules [49].

Immunohistochemical stains for melanocytic markers (eg, human melanoma black [HMB]-45, Melan-A, tyrosinase, microphthalmia transcription factor, NKI/C3) (picture 5) and muscle markers (eg, smooth muscle actin, pan-muscle actin, muscle myosin, calponin) are often positive [133,134]. While HMB-45 positivity is classically associated with the diagnosis of LAM, staining is sometimes sparse or absent, and while helpful, is not absolutely necessary for the diagnosis.

Immunohistochemical evaluation of lung tissue from LAM patients demonstrates immunoreactivity of LAM cells for estrogen receptor and progesterone receptor [135]. Although LAM nodules may demonstrate positivity for VEGF-C and VEGF-D, these stains are not routinely performed by most pathology departments [110].

Cytology — Cytology of pleural or peritoneal fluid or of needle aspirates of enlarged lymph nodes can occasionally provide a minimally invasive diagnosis. Case reports of patients with chylothorax or chyloperitoneum have identified LAM cell clusters (LCCs) that have the same immunoreactivity profile for HMB-45, hormone receptors, or smooth muscle actin to provide a definitive diagnosis [64,136-141]. Similarly, LAM cells may be identified by needle aspiration (laparoscopic or percutaneous) of an enlarged retroperitoneal, axial, or pelvic lymph node. While the true sensitivity of cytology is unknown, in our experience, the diagnostic yield is low.

Excluding tuberous sclerosis complex — TSC gene testing is not routinely indicated for diagnostic purposes in patients with LAM. Patients with sporadic LAM do not have germ line mutations in TSC genes, and DNA mutations are not present in cells from peripheral blood. A negative result in a patient with suspected TSC-LAM does not exclude the disease, since the test is only 85 percent sensitive. Although a positive result for a pathogenic (ie, functionally inactivating) mutation establishes the diagnosis of TSC [142] that result is unlikely in patients who do not have other disease manifestations of TSC, and the test is quite expensive. Patients with features of TSC should be referred to a specialist center for a formal diagnosis. (See 'Tuberous sclerosis complex' above and "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis".)

DIFFERENTIAL DIAGNOSIS — LAM can be confused with other diseases, such as asthma, emphysema, or pulmonary hypertension (PH), based on symptomatic presentation alone. Asthma may be suggested by the presence of allergies, wheeze, and intermittent exacerbations, emphysema by its association with cigarette smoking in an older population, and PH by syncope or increased jugular venous pressure; however, these features are nonspecific and their presence does not rule out LAM. Once a chest computed tomography (CT) shows cysts, the differential diagnosis narrows considerably.

Differential diagnosis of cystic lung disease — The differential diagnosis of cystic lung disease is broad (table 1) [143-147]. The most common conditions that mimic sporadic LAM are emphysema, pulmonary Langerhans cell histiocytosis (PLCH), lymphocytic interstitial pneumonia (LIP)/follicular bronchiolitis (FB), and Birt-Hogg-Dubé syndrome (BHD). Although some of these conditions can be distinguished from LAM clinically, radiologically, or serologically, atypical presentations exist and sometimes tissue biopsy is required for diagnostic certainty. (See 'Securing a diagnosis' above.)

Emphysema – Emphysema, with or without alpha-1 antitrypsin deficiency, is associated with obstructive physiology on pulmonary function tests and hyperlucent cyst-like changes on high resolution computed tomography (HRCT) of the chest. In contrast to cysts in LAM, cysts in emphysema may contain septae or centrilobular vessels, and are often upper lobe predominant with indiscernible borders. Although a definitive diagnosis can made histopathologically, the history of smoking and CT appearance is sufficiently diagnostic such that patients with emphysema are rarely subjected to biopsy for the purpose of confirming the diagnosis. (See "Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging", section on 'Diagnosis' and "Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency", section on 'Evaluation and diagnosis' and "Overview of pulmonary disease in injection drug users", section on 'Bullous lung disease and emphysema'.)

Birt-Hogg-Dubé Syndrome – BHD is an autosomal dominant disease caused by mutations in the folliculin (FLCN) gene, a tumor suppressor gene. It is a multisystem disorder that is associated with renal cysts and masses (including angiomyolipomas in very rare circumstances), cutaneous fibrofolliculomas and trichodiscomas, and cystic lung disease that frequently presents with recurrent spontaneous pneumothoraces. Lung cysts are found in over 80 percent of BHD patients, and are usually basilar or perivascular, subpleural, and crescent-shaped or elliptical [148,149]. While a family history may be present, many patients present without a positive family history, renal or skin manifestations. The diagnosis can be made by biopsy confirmation of fibrofolliculomas or by identifying the pathogenic FLCN gene mutation as there are no specific lung findings on biopsy other than cysts. (See "Hereditary kidney cancer syndromes", section on 'Birt-Hogg-Dubé syndrome'.)

Pulmonary Langerhans cell histiocytosis – PLCH (also known as eosinophilic granuloma) is associated with cystic changes on HRCT (often a late manifestation) that are typically upper lobe predominant, and more bizarrely-shaped, peribronchiolar, and thicker-walled than LAM cysts (image 9). In addition, PLCH is strongly associated with cigarette smoking (90 to 100 percent are smokers), has no female predilection, and is associated with stellate nodular findings on CT (which are typically early manifestations of the disease). Thus, thick-walled cystic changes in a young male smoker that spares the costophrenic angles are more likely due to PLCH, while thin-walled cysts in a nonsmoking female would be more consistent with LAM. The finding of more than 5 percent of Langerhans cells (CD-1a positive) on bronchoalveolar lavage is diagnostic of PLCH. Although the clinical and radiographic presentation of PLCH is often sufficiently distinctive that a presumptive diagnosis can be made, a definitive diagnosis of PLCH typically requires pathological confirmation, via either a transbronchial lung biopsy or a video assisted thorascopic-guided surgical lung biopsy. (See "Pulmonary Langerhans cell histiocytosis", section on 'Diagnostic evaluation'.)

Lymphocytic interstitial pneumonia/follicular bronchiolitis – Cystic changes can be seen in up to two-thirds of patients with LIP/FB. LIP/FB is usually seen in middle-aged women and in association with an autoimmune disorder (eg, Sjögren syndrome, systemic lupus erythematosus), or immunodeficiency state (eg, human immune deficiency virus, common variable immune deficiency). Diffuse thin-walled cystic change without other interstitial infiltrates can be the presenting manifestation of lupus or Sjögren related LIP/FB and can closely mimic LAM.

Characteristic features of cysts associated with LIP/FB include wide variation in size, a predilection for lower lung zone involvement, and perivascular distribution, internal structures and septations, and may occur together with centrilobular nodules and ground-glass attenuations (image 10). The cysts in FB are often sufficiently distinctive that a presumptive diagnosis can be made in patients with other corroborative features, such as a known diagnosis of Sjögren syndrome or lupus, sicca symptoms (eg, xerostomia and xerophthalmia may suggest Sjögren syndrome), or appropriate serologies. A definitive diagnosis of LIP/FB or Sjögren syndrome may require a biopsy (eg, lung, lip). (See "Lymphoid interstitial pneumonia in adults", section on 'Diagnosis' and "Diagnosis and classification of Sjögren's syndrome".)

Light chain deposition disease – Light chain deposition disease (LCDD) is a progressive cystic lung disease that can lead to respiratory failure. HRCT findings of LCDD can vary from multiple small round cysts in a diffuse distribution that mimics LAM to large cystic spaces associated with reticulonodular opacities mimicking PLCH [150]. Histologically, LCDD is characterized by kappa light chain deposition in the alveolar walls, small airways, and vessels accompanied by emphysematous changes and small airway dilation. (See "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)", section on 'Light chain deposition disease'.)

Sarcoidosis and advanced interstitial lung disease – Advanced sarcoidosis can be associated with development of lung cysts. These cysts tend to exhibit a perihilar or upper lobe distribution and are associated with fibrosis (image 11). Bilateral hilar adenopathy, which is rare in LAM, is common in sarcoidosis. Similarly, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis can be associated with lung cysts due to scarring in advanced disease. These diseases are easily differentiated from LAM by virtue of the other radiographic findings (eg, reticulations, scarring, nodules), and by histopathological analysis in those cases that are biopsied. (See "Clinical manifestations and diagnosis of pulmonary sarcoidosis", section on 'Chest radiograph' and "Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)", section on 'Chronic HP'.)

Others – Less common causes of lung cysts include pneumatoceles from previous infection, barotrauma or physical trauma, or tumors (metastatic sarcomas, epithelial tumors or lymphomas). Infectious causes of lung cysts include Pneumocystis jirovecii pneumonia, chronic paracoccidioidomycosis or coccidiomycosis, and recurrent human papilloma virus infection. In addition, hyper-immunoglobulin E syndrome, amyloidosis, neurofibromatosis, Marfan syndrome, and Ehlers-Danlos syndrome have been associated with lung cysts.

Differential diagnosis of pneumothorax – Although a CT chest is not recommended in every patient with pneumothorax [151], our practice is to have a low threshold for obtaining a HRCT, particularly in young, nonsmoking women. Data from countries that routinely perform CT for primary spontaneous pneumothorax (PSP) may diagnose LAM at an earlier age, and additional data suggest that performing a chest CT in patients with apparent PSP to screen for cystic lung diseases (LAM, BHD, and PLCH) is cost-effective [34,96,152]. (See "Primary spontaneous pneumothorax in adults" and "Secondary spontaneous pneumothorax in adults" and "Imaging of pneumothorax".)

Differential diagnosis of chylothorax – The various etiologies of chylous accumulations, including trauma, lymphoma, and congenital lymphatic anomalies, are listed in the table (table 2). LAM can be distinguished from other causes of chylothorax by identifying the presence of LAM cell clusters in chylous fluid, although this finding is not always present. Determination of the cause of chylothorax is discussed separately. (See "Etiology, clinical presentation, and diagnosis of chylothorax", section on 'Etiology of chylothorax'.)

ASSESSMENT OF DISEASE EXTENT — Sporadic lymphangioleiomyomatosis (LAM) is a multisystem, progressive disease that requires an initial assessment of extent of disease followed by longitudinal studies to identify progression and complications. For those with a clinical diagnosis of LAM, an opportunity may arise during this period to make a definitive diagnosis from lung tissue obtained during thorascopic pleurodesis or from chyle that may develop the course of disease.

Much of the information that is needed to assess the extent of the disease is available from tests obtained during the diagnostic investigation. If not already performed, we suggest the following:

Abdominal-pelvic imaging – Most experts obtain additional abdominal-pelvic imaging to fully assess for renal angiomyolipomas by computed tomography and/or magnetic resonance imaging [57]. For patients with a chylothorax or peripheral lymphedema, such imaging can also detect intra-abdominal fluid collections and lymphatic manifestations including lymphangioleiomyomas and lymphadenopathy.

Exercise capacity – For patients with dyspnea on exertion or a reduced diffusing capacity for carbon monoxide (DLCO), we obtain six-minute walk testing and/or arterial blood gases for those with resting desaturations <89 percent. (See 'Pulmonary function tests' above.)

Others – While some experts routinely perform testing, we use a symptom-directed approach to detect the following:

Pulmonary hypertension (eg, echocardiography)

Osteoporosis (nuclear bone scanning)

Cerebral meningioma (magnetic resonance imaging)

The value of serial vascular endothelial growth factor-D (VEGF-D) levels in untreated patients with LAM is unclear. Its potential role in assisting treatment decisions is discussed separately. (See "Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Monitoring clinical response'.)

We do not routinely perform lymphatic imaging, 18-fluorodeoxyglucose positron emission tomographic (PET) imaging, sleep study, or bone density scans unless an indication to do so is present.

Age-appropriate screening for breast and gynecological cancer, as well as for osteoporosis (found in up to 70 percent) [153], is also prudent. (See "Preventive care in adults: Recommendations", section on 'Cancer' and "Screening for osteoporosis".)

ADDITIONAL RESOURCES — The LAM Foundation offers information and patient support, and has identified LAM specialty clinics across the United States; a list of these and other useful information can be found at The LAM Foundation, the Tuberous Sclerosis Alliance, LAM Action, and the Rare Lung Disease Consortium.


Lymphangioleiomyomatosis (LAM) is a rare multisystem disease that mostly afflicts young women. The term sporadic LAM is used for patients who do not have tuberous sclerosis complex (TSC). (See 'Introduction' above and 'Definition' above.)

LAM should be suspected in a young female who presents with a spontaneous pneumothorax, unexplained dyspnea, pleural or peritoneal chyle, TSC, or a renal angiomyolipoma (AML). With increasing use of computed tomography (CT), lung cysts characteristic of the diagnosis are often discovered incidentally in asymptomatic patients. Other manifestations of LAM include pulmonary hypertension, lymphadenopathy, or lymphangioleiomyomas. (See 'Clinical manifestations' above.)

When LAM is suspected, the following should be performed:

Pulmonary function tests (PFTs), including spirometry with bronchodilator testing, lung volumes, and diffusing capacity for carbon monoxide (DLCO). While airflow obstruction and/or a reduced DLCO are typical, normal PFTS do not preclude the diagnosis. (See 'Pulmonary function tests' above.)

Noncontrast high resolution CT (HRCT) should be obtained to demonstrate pulmonary cysts characteristic of the disease. Cysts are classically multiple (>10), diffuse, round, well-defined, bilateral, without lobar predominance, and thin-walled. (See 'Chest computed tomography' above.)

If characteristic cysts are found, we suggest the following be performed (algorithm 1):

A thorough history and examination for the symptoms and signs of tuberous sclerosis complex. (See "Tuberous sclerosis complex: Genetics, clinical features, and diagnosis".)

Abdominopelvic imaging to primarily look for the presence of AMLs, but also for effusions suggestive of chyle, lymphadenopathy, and/or lymphangioleiomyomas. (See 'Abdominal imaging' above.)

Measurement of serum vascular endothelial growth factor-D (VEGF-D); level ≥800 pg/mL distinguishes LAM from other cystic lung diseases. This can be obtained as a send out test through the Translational Trials Laboratory at Cincinnati Children's. Other serologic tests, including alpha-1 antitrypsin (AAT) levels, rheumatoid factor, anti-nuclear antibody, and Sjögren related antibodies (SSA/Ro and SSB/La antibodies), may be performed to exclude disorders that can mimic LAM. (See 'Laboratory' above.)

When considering a diagnosis of LAM, the ideal goal is to obtain the most definitive possible diagnosis using the least invasive strategy as is feasible (algorithm 1). Utilizing such strategies reduces the need for biopsy and is sufficient to support the use of mechanistic target of rapamycin inhibitors for treatment. Our approach is the following:

In patients who have characteristic cysts on chest CT and known TSC, AML, chylous effusions, classic CT appearance of lymphangioleiomyoma, and/or a VEGF-D level ≥800pg/mL, a lung biopsy can be avoided and a clinically confident nonpathologic diagnosis may be made. A definitive pathologic diagnosis may occasionally be indicated in this population in patients who have atypical presentations (especially when considering interventions entailing risk such as mTOR inhibitor therapy), suspicion of an alternate diagnosis, and patient preferences for certainty. (See 'Characteristic cysts with supportive features' above and 'Vascular endothelial growth factor-D positive' above and 'Atypical presentations' above and 'Clinical nonpathologic diagnosis' above.)

In most patients who have characteristic cysts on chest CT without any of the listed supporting features, we suggest a tissue biopsy be performed, if feasible. Options include lung biopsy (eg, transbronchial and surgical) or lymph node biopsy (needle aspiration or resectional). The decision to proceed with biopsy and choosing among the options should be individualized and is influenced by factors including the presenting manifestations, clinician experience, disease severity, and values of the patient. The definitive diagnosis of LAM is made by the histopathologic confirmation of lung cysts and histopathologic or cytologic identification of LAM cells in lung, lymph node, or body fluid. (See 'Characteristic cysts alone on computed tomography' above and 'Choosing transbronchial or surgical lung biopsy' above and 'Definitive pathologic diagnosis' above.)

In patients with atypical presentations, the approach should be individualized using the minimally invasive approach, when appropriate. (See 'Atypical presentations' above.)

Conditions that are in the differential diagnosis of LAM include other causes of cystic lung disease, pneumothorax, and chylothorax. (See 'Differential diagnosis' above.)

Sporadic LAM is a multisystem, progressive disease that requires assessment of disease extent. For those with a clinical diagnosis of LAM, an opportunity may arise during follow-up to make a definitive diagnosis from lung tissue obtained during thoracoscopic pleurodesis or from chyle that may develop the course of disease progression. (See 'Assessment of disease extent' above.)

Use of UpToDate is subject to the  Subscription and License Agreement.


  1. Kalassian KG, Doyle R, Kao P, et al. Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med 1997; 155:1183.
  2. Sullivan EJ. Lymphangioleiomyomatosis: a review. Chest 1998; 114:1689.
  3. NHLBI Workshop Summary. Report of workshop on lymphangioleiomyomatosis. National Heart, Lung, and Blood Institute. Am J Respir Crit Care Med 1999; 159:679.
  4. Johnson S. Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax 1999; 54:254.
  5. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000; 31:1242.
  6. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000; 216:147.
  7. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173:105.
  8. Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med 2002; 96:1.
  9. Baldi BG, Freitas CS, Araujo MS, et al. Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:129.
  10. Restrepo-Gualteros SM, Rodriguez-Martinez CE, Jaramillo-Barberi LE, et al. Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM). Allergol Immunopathol (Madr) 2015; 43:111.
  11. Richter MJ, Baumgartner R, Leuchte HH. [Chylothorax in an 87-year-old patient]. Internist (Berl) 2013; 54:105.
  12. Kebria M, Black D, Borelli C, et al. Primary retroperitoneal lymphangioleiomyomatosis in a postmenopausal woman: a case report and review of the literature. Int J Gynecol Cancer 2007; 17:528.
  13. Zanella A, Toppan P, Nitti D, Lise M. Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate). Tumori 1996; 82:96.
  14. Nagy B, Nábrády Z, Nemes Z. Pulmonary lymphangiomyomatosis in a preadolescent girl. N Engl J Med 1998; 338:473.
  15. Ho TB, Hull JH, Hughes NC. An 86-year-old female with lymphangioleiomyomatosis. Eur Respir J 2006; 28:1065.
  16. Ciftci AO, Sanlialp I, Tanyel FC, Buyukpamukçu N. The association of pulmonary lymphangioleiomyomatosis with renal and hepatic angiomyolipomas in a prepubertal girl: a previously unreported entity. Respiration 2007; 74:335.
  17. Cohen MM, Pollock-BarZiv S, Johnson SR. Emerging clinical picture of lymphangioleiomyomatosis. Thorax 2005; 60:875.
  18. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55:1052.
  19. Yockey CC, Riepe RE, Ryan K. Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kans Med 1986; 87:277.
  20. Cleary-Goldman J, Sanghvi AV, Nakhuda GS, Robinson JN. Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy. J Matern Fetal Neonatal Med 2004; 15:132.
  21. Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet 1996; 52:289.
  22. Mitra S, Ghosal AG, Bhattacharya P. Pregnancy unmasking lymphangioleiomyomatosis. J Assoc Physicians India 2004; 52:828.
  23. Fujimoto M, Ohara N, Sasaki H, et al. Pregnancy complicated with pulmonary lymphangioleiomyomatosis: case report. Clin Exp Obstet Gynecol 2005; 32:199.
  24. McLoughlin L, Thomas G, Hasan K. Pregnancy and lymphangioleiomyomatosis: anaesthetic management. Int J Obstet Anesth 2003; 12:40.
  25. Warren SE, Lee D, Martin V, Messink W. Pulmonary lymphangiomyomatosis causing bilateral pneumothorax during pregnancy. Ann Thorac Surg 1993; 55:998.
  26. Cohen MM, Freyer AM, Johnson SR. Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 2009; 103:766.
  27. Raft J, Lalot JM, Meistelman C, Longrois D. [Renal angiomyolipoma rupture during pregnancy]. Gynecol Obstet Fertil 2006; 34:917.
  28. Storm DW, Mowad JJ. Conservative management of a bleeding renal angiomyolipoma in pregnancy. Obstet Gynecol 2006; 107:490.
  29. Morales JP, Georganas M, Khan MS, et al. Embolization of a bleeding renal angiomyolipoma in pregnancy: case report and review. Cardiovasc Intervent Radiol 2005; 28:265.
  30. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis. A review. Am J Pathol 1975; 79:348.
  31. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323:1254.
  32. Crausman RS, Jennings CA, Mortenson RL, et al. Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med 1996; 153:1368.
  33. Park HY, Nam HS, Chung MP, et al. A nationwide survey of lymphangioleiomyomatosis in Korea: recent increase in newly diagnosed patients. J Korean Med Sci 2010; 25:1182.
  34. Hayashida M, Seyama K, Inoue Y, et al. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 2007; 12:523.
  35. Lama A, Ferreiro L, Golpe A, et al. Characteristics of Patients with Lymphangioleiomyomatosis and Pleural Effusion: A Systematic Review. Respiration 2016; 91:256.
  36. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 1999; 78:321.
  37. Taveira-DaSilva AM, Steagall WK, Rabel A, et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest 2009; 136:1596.
  38. Yen KT, Putzke JD, Staats BA, Burger CD. The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. Respirology 2005; 10:643.
  39. Berkman N, Bloom A, Cohen P, et al. Bilateral spontaneous pneumothorax as the presenting feature in lymphangioleiomyomatosis. Respir Med 1995; 89:381.
  40. Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006; 129:1274.
  41. Steagall WK, Glasgow CG, Hathaway OM, et al. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2007; 293:L800.
  42. Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest 2003; 123:623.
  43. Moua T, Olson EJ, Jean HC, Ryu JH. Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186:389.
  44. Kinoshita Y, Sakamoto A, Hidaka K. Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis. BMJ Case Rep 2014; 2014.
  45. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154:797.
  46. Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007; 132:1573.
  47. Zafar MA, McCormack FX, Rahman S, et al. Pulmonary vascular shunts in exercise-intolerant patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 2013; 188:1167.
  48. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40:630.
  49. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151:527.
  50. Antón E, Casanova A, Xaubet A, et al. Lymphangioleiomyomatosis: a study of 72 patients from the Spanish registry. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:85.
  51. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115:1041.
  52. Bosniak MA, Megibow AJ, Hulnick DH, et al. CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat. AJR Am J Roentgenol 1988; 151:497.
  53. Bernstein SM, Newell JD Jr, Adamczyk D, et al. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med 1995; 152:2138.
  54. Ryu JH, Hartman TE, Torres VE, Decker PA. Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest 2012; 141:163.
  55. Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 2007; 242:277.
  56. Gupta R, Kitaichi M, Inoue Y, et al. Lymphatic manifestations of lymphangioleiomyomatosis. Lymphology 2014; 47:106.
  57. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35:14.
  58. Derweduwen AM, Verbeken E, Stas M, et al. Extrapulmonary lymphangioleiomyomatosis: a wolf in sheep's clothing. Thorax 2013; 68:111.
  59. Avila NA, Bechtle J, Dwyer AJ, et al. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 2001; 221:415.
  60. Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis. Chest 2015; 148:1027.
  61. Hoshika Y, Hamamoto T, Sato K, et al. Prevalence and clinical features of lymphedema in patients with lymphangioleiomyomatosis. Respir Med 2013; 107:1253.
  62. Seaman DM, Meyer CA, Gilman MD, McCormack FX. Diffuse cystic lung disease at high-resolution CT. AJR Am J Roentgenol 2011; 196:1305.
  63. Tobino K, Johkoh T, Fujimoto K, et al. Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients. Eur J Radiol 2015; 84:534.
  64. Berner A, Franzen S, Heilo A. Fine needle aspiration cytology as a diagnostic approach to lymphangioleiomyomatosis. A case report. Acta Cytol 1997; 41:877.
  65. Kamitani T, Yabuuchi H, Soeda H, et al. A case of lymphangioleiomyomatosis affecting the supraclavicular lymph nodes. J Comput Assist Tomogr 2006; 30:279.
  66. Matthews LM. Fine needle aspiration diagnosis of lymphangiomyomatosis. A case report. Acta Cytol 1999; 43:1155.
  67. Schoolmeester JK, Park KJ. Incidental Nodal Lymphangioleiomyomatosis Is Not a Harbinger of Pulmonary Lymphangioleiomyomatosis: A Study of 19 Cases With Evaluation of Diagnostic Immunohistochemistry. Am J Surg Pathol 2015; 39:1404.
  68. Rabban JT, Firetag B, Sangoi AR, et al. Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic Cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex. Am J Surg Pathol 2015; 39:1015.
  69. Longacre TA, Hendrickson MR, Kapp DS, Teng NN. Lymphangioleiomyomatosis of the uterus simulating high-stage endometrial stromal sarcoma. Gynecol Oncol 1996; 63:404.
  70. Ruco LP, Pilozzi E, Wedard BM, et al. Epithelioid lymphangioleiomyomatosis-like tumour of the uterus in a patient without tuberous sclerosis: a lesion mimicking epithelioid leiomyosarcoma. Histopathology 1998; 33:91.
  71. Jaiswal VR, Baird J, Fleming J, et al. Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med 2003; 127:879.
  72. Hayashi T, Kumasaka T, Mitani K, et al. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol 2011; 35:1776.
  73. Moss J, DeCastro R, Patronas NJ, Taveira-DaSilva A. Meningiomas in lymphangioleiomyomatosis. JAMA 2001; 286:1879.
  74. Franz DN. Meningiomas in women with lymphangioleiomyomatosis. JAMA 2002; 287:1397.
  75. Taveira-Dasilva AM, Rabel A, Gochuico BR, et al. Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril 2011; 96:711.
  76. Fu W, Li Y, Li H, et al. Solitary extrapulmonary lymphangioleiomyomatosis of the liver: A case report and literature review. Exp Ther Med 2016; 12:1499.
  77. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med 2016; 194:748.
  78. Feemster LC, Lyons PG, Chatterjee RS, et al. Summary for Clinicians: Lymphangioleiomyomatosis Diagnosis and Management Clinical Practice Guideline. Ann Am Thorac Soc 2017; 14:1073.
  79. Medeiros P Jr, Lorenzi-Filho G, Pimenta SP, et al. Sleep desaturation and its relationship to lung function, exercise and quality of life in LAM. Respir Med 2012; 106:420.
  80. Burger CD, Hyatt RE, Staats BA. Pulmonary mechanics in lymphangioleiomyomatosis. Am Rev Respir Dis 1991; 143:1030.
  81. Baldi BG, Albuquerque AL, Pimenta SP, et al. Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2012; 186:341.
  82. Hayashi T, Kumasaka T, Mitani K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol 2016; 50:34.
  83. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126:1867.
  84. Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 2001; 25:479.
  85. Avila NA, Kelly JA, Dwyer AJ, et al. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 2002; 223:189.
  86. Paciocco G, Uslenghi E, Bianchi A, et al. Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 2004; 125:135.
  87. Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001; 164:1072.
  88. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2003; 168:1427.
  89. Bahmer T, Watz H, Waschki B, et al. Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. Thorax 2016; 71:662.
  90. Hayashida M, Yasuo M, Hanaoka M, et al. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. Respir Investig 2016; 54:193.
  91. Taveira-DaSilva AM, Julien-Williams P, Jones AM, Moss J. Incidence of Pneumothorax in Patients With Lymphangioleiomyomatosis Undergoing Pulmonary Function and Exercise Testing. Chest 2016; 150:e5.
  92. Crausman RS, Lynch DA, Mortenson RL, et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 1996; 109:131.
  93. Berger JL. X-ray of the month. Pulmonary lymphangioleiomyomatosis. J Tenn Med Assoc 1980; 73:657.
  94. Lenoir S, Grenier P, Brauner MW, et al. Pulmonary lymphangiomyomatosis and tuberous sclerosis: comparison of radiographic and thin-section CT findings. Radiology 1990; 175:329.
  95. Müller NL, Chiles C, Kullnig P. Pulmonary lymphangiomyomatosis: correlation of CT with radiographic and functional findings. Radiology 1990; 175:335.
  96. Hagaman JT, Schauer DP, McCormack FX, Kinder BW. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med 2010; 181:1376.
  97. Rappaport DC, Weisbrod GL, Herman SJ, Chamberlain DW. Pulmonary lymphangioleiomyomatosis: high-resolution CT findings in four cases. AJR Am J Roentgenol 1989; 152:961.
  98. Templeton PA, McLoud TC, Müller NL, et al. Pulmonary lymphangioleiomyomatosis: CT and pathologic findings. J Comput Assist Tomogr 1989; 13:54.
  99. Avila NA, Dwyer AJ, Moss J. Imaging features of lymphangioleiomyomatosis: diagnostic pitfalls. AJR Am J Roentgenol 2011; 196:982.
  100. Avila NA, Dwyer AJ, Rabel A, et al. CT of pleural abnormalities in lymphangioleiomyomatosis and comparison of pleural findings after different types of pleurodesis. AJR Am J Roentgenol 2006; 186:1007.
  101. Narayanaswamy S, Kamath S, Williams M. CT appearances of talc pleurodesis. Clin Radiol 2007; 62:233.
  102. Young LR, Franz DN, Nagarkatte P, et al. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest 2009; 136:926.
  103. Baldi BG, Pimenta SP, Kawassaki Ade M, et al. Pulmonary arterial involvement leading to alveolar hemorrhage in lymphangioleiomyomatosis. Clinics (Sao Paulo) 2011; 66:1301.
  104. Muir TE, Leslie KO, Popper H, et al. Micronodular pneumocyte hyperplasia. Am J Surg Pathol 1998; 22:465.
  105. Engels K, Stauber R, Magnussen H, et al. Angiomyolipomas are indicator lesions for sporadic lymphangioleiomyomatosis in women. Eur Urol 2009; 55:755.
  106. Yeoh ZW, Navaratnam V, Bhatt R, et al. Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance. Orphanet J Rare Dis 2014; 9:151.
  107. Itkin M, McCormack FX. Non-malignant thoracic lymphatic disorders. Clinics in Chest Medicine.
  108. Baldi BG, Araujo MS, Freitas CS, et al. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung 2014; 192:967.
  109. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138:674.
  110. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4:143.
  111. Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009; 135:1293.
  112. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008; 358:199.
  113. Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res 2012; 13:34.
  114. Radzikowska E, Jaguś P, Sobiecka M, et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med 2015; 109:1469.
  115. Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 2013; 107:263.
  116. Radzikowska E, Jaguś P, Skoczylas A, et al. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases. Pol Arch Med Wewn 2013; 123:533.
  117. Vortmeyer AO, Lubensky IA, Skarulis M, et al. Multiple endocrine neoplasia type 1: atypical presentation, clinical course, and genetic analysis of multiple tumors. Mod Pathol 1999; 12:919.
  118. Tobino K, Seyama K. Birt-Hogg-Dubé syndrome with renal angiomyolipoma. Intern Med 2012; 51:1279.
  119. Byrne M, Mallipeddi R, Pichert G, Whittaker S. Birt-Hogg-Dubé syndrome with a renal angiomyolipoma: further evidence of a relationship between Birt-Hogg-Dubé syndrome and tuberous sclerosis complex. Australas J Dermatol 2012; 53:151.
  120. Cottin V, Lacronique J, Denis L, et al. Diagnostic value of serum VEGF-D in consecutive patients with lymphangioleiomyomatosis. Eur Respir J 2011; 38:627.
  121. Bonelli FS, Hartman TE, Swensen SJ, Sherrick A. Accuracy of high-resolution CT in diagnosing lung diseases. AJR Am J Roentgenol 1998; 170:1507.
  122. Koyama M, Johkoh T, Honda O, et al. Chronic cystic lung disease: diagnostic accuracy of high-resolution CT in 92 patients. AJR Am J Roentgenol 2003; 180:827.
  123. Gupta N, Meraj R, Tanase D, et al. Accuracy of chest high-resolution computed tomography in diagnosing diffuse cystic lung diseases. Eur Respir J 2015; 46:1196.
  124. Matthews TJ, Hornall D, Sheppard MN. Comparison of the use of antibodies to alpha smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis. J Clin Pathol 1993; 46:479.
  125. Chan JK, Tsang WY, Pau MY, et al. Lymphangiomyomatosis and angiomyolipoma: closely related entities characterized by hamartomatous proliferation of HMB-45-positive smooth muscle. Histopathology 1993; 22:445.
  126. Bonetti F, Chiodera PL, Pea M, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. Am J Surg Pathol 1993; 17:1092.
  127. Hoon V, Thung SN, Kaneko M, Unger PD. HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch Pathol Lab Med 1994; 118:732.
  128. Guinee DG Jr, Feuerstein I, Koss MN, Travis WD. Pulmonary lymphangioleiomyomatosis. Diagnosis based on results of transbronchial biopsy and immunohistochemical studies and correlation with high-resolution computed tomography findings. Arch Pathol Lab Med 1994; 118:846.
  129. Meraj R, Wikenheiser-Brokamp KA, Young LR, et al. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med 2012; 6:395.
  130. Harari S, Torre O, Cassandro R, et al. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med 2012; 106:1286.
  131. Ye L, Jin M, Bai C. Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland China. Respir Med 2010; 104:1521.
  132. McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012; 186:1210.
  133. Martignoni G, Pea M, Reghellin D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med 2010; 134:33.
  134. Hornick JL, Pan C-C. PEComa. In: World Health Organization classification of tumours of soft tissue and bone, 4th, Fletcher CDM, Brodge JA, Hogendoorn PCW, Mertens F. (Eds), IARC, Lyon 2013. p.230.
  135. Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 2000; 67:311.
  136. Mitani K, Kumasaka T, Takemura H, et al. Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol 2009; 53:402.
  137. Yamauchi M, Nakahara H, Uyama K, et al. Cytologic finding of chyloascites in lymphangioleiomyomatosis. A case report. Acta Cytol 2000; 44:1081.
  138. Itami M, Teshima S, Asakuma Y, et al. Pulmonary lymphangiomyomatosis diagnosed by effusion cytology. A case report. Acta Cytol 1997; 41:522.
  139. Fan D, Ding L, Liu H, et al. Effusion cytology: an effective method for the diagnosis of pulmonary lymphangioleiomyomatosis. J Thorac Dis 2014; 6:E54.
  140. Rivera G, Gokaslan T, Kurian EM. Lymphangioleiomyomatosis diagnosed by effusion cytology: A case report. J Cytol 2015; 32:287.
  141. Grzegorek I, Zuba-Surma E, Chabowski M, et al. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis. Anticancer Res 2015; 35:3341.
  142. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:243.
  143. Ferreira Francisco FA, Soares Souza A Jr, Zanetti G, Marchiori E. Multiple cystic lung disease. Eur Respir Rev 2015; 24:552.
  144. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part I. Am J Respir Crit Care Med 2015; 191:1354.
  145. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part II. Am J Respir Crit Care Med 2015; 192:17.
  146. Gupta N, Wikenheiser-Brokamp KA, Fischer A, McCormack FX. Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome. Ann Am Thorac Soc 2016; 13:371.
  147. Bhardwaj H, Bhardwaj B. Differentiating pulmonary lymphangioleiomyomatosis from pulmonary langerhans cell histiocytosis and Birt-Hogg-Dube syndrome. Lung India 2013; 30:372.
  148. Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med 2007; 175:1044.
  149. Gupta N, Seyama K, McCormack FX. Pulmonary manifestations of Birt-Hogg-Dubé syndrome. Fam Cancer 2013; 12:387.
  150. Colombat M, Stern M, Groussard O, et al. Pulmonary cystic disorder related to light chain deposition disease. Am J Respir Crit Care Med 2006; 173:777.
  151. Baumann MH, Strange C, Heffner JE, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119:590.
  152. Gupta N, Langenderfer D, McCormack FX, et al. HRCT screening for diffuse cystic lung diseases in patients presenting with spontaneous pneumothorax is cost-effective [abstract]. Am J Respir Crit Care Med 2016; 104:A6261.
  153. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, et al. Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2005; 171:61.
Topic 107651 Version 8.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.